Life Sciences Tax Incentives: R&D Credits and Section 174A

Life sciences companies developing drugs, devices, and biotech products can draw on a stack of federal tax incentives that directly reduce the cost of research, and several of them became more generous in 2025 under the One Big Beautiful Bill Act. The core life sciences tax incentives are the Section 41 R&D credit, a payroll-tax version of that credit for pre-revenue startups, immediate expensing of domestic research costs under new Section 174A, permanent 100 percent bonus depreciation on lab equipment, the orphan drug clinical testing credit, and the qualified small business stock gain exclusion for early investors. State programs sit on top of these. Missing even one can mean leaving six- or seven-figure savings unclaimed.

The Section 41 R&D Credit

Section 41 of the Internal Revenue Code gives you a dollar-for-dollar credit against federal income tax for qualified research expenses.1Office of the Law Revision Counsel. 26 USC 41 – Credit for Increasing Research Activities This is not a deduction. It reduces the tax you actually owe, which makes it the most valuable recurring benefit most life sciences companies will ever claim.

To qualify, spending has to pass a four-part test: the activity must be eligible for Section 174 treatment, rely on principles of physical or biological science, engineering, or computer science, aim to develop or improve a specific business component, and involve a process of experimentation for at least 80 percent of the work.2eCFR. 26 CFR 1.41-4 – Qualified Research for Expenditures Paid or Incurred Drug development and device testing are inherently experimental, so life sciences companies clear this bar more easily than most industries. Documentation is still what wins on audit.

Three categories of spending count. Wages for employees who perform, supervise, or support qualified research. Supplies consumed in the research process, including reagents, chemicals, lab animals, and prototype materials. And 65 percent of amounts paid to outside contractors for qualified work.1Office of the Law Revision Counsel. 26 USC 41 – Credit for Increasing Research Activities Only domestic research qualifies. Work performed outside the United States is excluded from the credit calculation.

Which Calculation Method to Use

You choose between two methods. The regular credit under Section 41(c) compares current-year expenses to a base built from historical spending and gross receipts going back to 1984, which many companies simply cannot reconstruct. The alternative simplified credit is 14 percent of current-year qualified expenses above 50 percent of the average for the prior three years, or 6 percent of current-year expenses if you had none in any of the three prior years.1Office of the Law Revision Counsel. 26 USC 41 – Credit for Increasing Research Activities Most life sciences companies elect the ASC. Once elected, it applies to all future years unless affirmatively revoked on a timely filed return.3Internal Revenue Service. Instructions for Form 6765

The Payroll-Tax Offset for Pre-Revenue Startups

Early-stage biotech and pharma companies often have no income tax liability, so the R&D credit would sit unused. Section 41(h) fixes that. A qualified small business can elect to apply up to $500,000 of R&D credits per year against its share of payroll taxes instead.4Internal Revenue Service. Research Credit Against Payroll Tax for Small Businesses

To qualify, your company must have gross receipts under $5 million for the credit year and cannot have had gross receipts for any tax year before the five-year period ending with the credit year.1Office of the Law Revision Counsel. 26 USC 41 – Credit for Increasing Research Activities The $500,000 cap was raised from $250,000 for tax years beginning after December 31, 2022.5Internal Revenue Service. Qualified Small Business Payroll Tax Credit for Increasing Research Activities The credit reduces the employer share of Social Security taxes each quarter, so it shows up as real cash flow during the years you need it most.

Immediate Expensing of Domestic Research Under Section 174A

From 2022 through 2024, the Tax Cuts and Jobs Act required companies to capitalize all research and experimental expenditures and amortize them over five years domestically or fifteen years for foreign work. That was painful for life sciences companies used to deducting research costs immediately.

The One Big Beautiful Bill Act reversed the domestic rule. New Section 174A permanently allows full and immediate expensing of domestic research and experimental expenditures for tax years beginning after December 31, 2024. Foreign research costs still must be capitalized and amortized over fifteen years under Section 174.6Office of the Law Revision Counsel. 26 USC 174 – Amortization of Research and Experimental Expenditures

Section 174A reaches a broader set of costs than the Section 41 credit. It picks up patent attorney fees, software licenses, fringe benefits, depreciation on research equipment, and 100 percent of contractor costs, compared with the 65 percent limit under the credit. If you run clinical trials overseas or use foreign CROs, those costs still fall into the slow fifteen-year track. Companies with mixed portfolios need to track where each dollar of research is performed.

Full Bonus Depreciation on Lab Equipment

Laboratory instruments, manufacturing equipment, and specialized machinery qualify as tangible personal property eligible for bonus depreciation. The One Big Beautiful Bill Act made 100 percent bonus depreciation permanent for qualified property acquired after January 19, 2025.7Internal Revenue Service. Interim Guidance on Additional First Year Depreciation Deduction under Section 168(k) Bonus depreciation had already dropped to 60 percent for 2024 and was scheduled to keep declining.

A company buying a $2 million mass spectrometer or building out a cleanroom in 2026 can now deduct the full cost in the year the equipment is placed in service rather than spreading it over five or seven years. This applies to new and used property, as long as it is new to the taxpayer. Equipment acquired before January 20, 2025 remains on the old phasedown schedule.

The Orphan Drug Clinical Testing Credit

Section 45C targets treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the United States, or conditions where the cost of drug development cannot reasonably be recovered through U.S. sales.8Office of the Law Revision Counsel. 26 USC 45C – Clinical Testing Expenses for Certain Drugs for Rare Diseases or Conditions The credit equals 25 percent of qualified clinical testing expenses. The rate was cut from the original 50 percent by the Tax Cuts and Jobs Act for tax years beginning after 2017.

The drug must first receive orphan designation from the FDA under Section 526 of the Federal Food, Drug, and Cosmetic Act. Only clinical testing expenses incurred after that designation and before final marketing approval count.8Office of the Law Revision Counsel. 26 USC 45C – Clinical Testing Expenses for Certain Drugs for Rare Diseases or Conditions Preclinical work and post-approval studies are excluded. The credit is claimed on Form 8820, which requires detailed cost breakdowns tied to each designated drug. A Phase III trial with $40 million in qualified expenses generates a $10 million credit, so the arithmetic is worth the tracking. Start segregating clinical testing costs from general R&D the day designation is granted. Retroactive allocation invites audit trouble.

Capital Gains Exclusion for Early Investors

Section 1202 excludes a portion of capital gains from the sale of qualified small business stock. The One Big Beautiful Bill Act expanded the benefit substantially for stock issued after July 4, 2025.9Office of the Law Revision Counsel. 26 USC 1202 – Partial Exclusion for Gain from Certain Small Business Stock

The exclusion now works on a tiered holding period: 50 percent of gain excluded at three years, 75 percent at four years, and 100 percent at five years or more. The per-issuer gain cap rose to $15 million (or ten times your adjusted basis, whichever is greater) for stock acquired after July 4, 2025, up from $10 million. Both the $15 million cap and the gross asset threshold are indexed for inflation starting in 2027.9Office of the Law Revision Counsel. 26 USC 1202 – Partial Exclusion for Gain from Certain Small Business Stock

The issuing company must be a domestic C corporation with aggregate gross assets of $75 million or less at the time the stock is issued. Stock must be acquired at original issuance in exchange for money, property, or services. Secondary-market purchases do not qualify. For early biotech investors, a successful exit after five years can be entirely federal tax-free up to the $15 million cap.

Carryforwards and the Section 280C Election

The R&D and orphan drug credits both flow into the general business credit under Section 38. If your credits exceed your tax for the year, the excess carries back one year and forward up to twenty.10Office of the Law Revision Counsel. 26 USC 39 – Carryback and Carryforward of Unused Credits Companies that spend years in development can build significant carryforward balances, but anything not used within twenty years expires.

You also make a choice on every return claiming the credit. Section 280C requires that if you take the full credit, you reduce your research expense deduction by the same amount to prevent a double benefit.11Office of the Law Revision Counsel. 26 USC 280C – Certain Expenses for Which Credits Are Allowable The alternative is to elect a reduced credit, which lets you keep the full deduction but shrinks the credit by the maximum corporate tax rate of 21 percent. Most companies pick the reduced credit because it avoids the deduction-adjustment bookkeeping. The election is made on Form 6765 and is irrevocable for that tax year.

State-Level R&D Credits and Equipment Exemptions

Most states run their own R&D credits, with rates ranging from around 3 percent to as high as 24 percent of qualified expenses. Some states adopt the federal four-part test; others impose their own eligibility rules. States with established biotech hubs tend to combine R&D credits with job creation incentives, sales tax exemptions on lab equipment, and property tax abatements for certified facilities.

Refundable R&D credits are especially valuable for pre-revenue companies, since they pay out as cash even when there is no state tax to offset. Angel investor credits, often around 25 percent of qualifying investment, are another common tool. Sales tax exemptions on research equipment typically cover tangible personal property used directly in research, including lab instruments, testing equipment, and consumable supplies. State rules change frequently as economic development priorities shift, so confirm current terms in your jurisdiction before basing capital decisions on them.

Documentation and Filing

R&D credit claims are among the most audit-prone items on a corporate return. The standard is not just that you spent money on research. You have to show that each project and each dollar satisfies the four-part test at the individual business component level.

Keep payroll records that show what percentage of each researcher’s time went to qualifying activities, broken down by project. Trace supply invoices to specific experiments. Draft contractor agreements with a scope of work clear enough to establish that qualified research was performed. Lab notebooks, experimental protocols, design reviews, and test results provide the technical narrative connecting expenses to the four-part test.

The R&D credit is calculated on Form 6765, which has separate sections for the regular method and the ASC.12Internal Revenue Service. About Form 6765, Credit for Increasing Research Activities The orphan drug credit uses Form 8820. Both feed into Form 3800, the general business credit form, which attaches to your income tax return. If you are switching how you account for research costs, particularly moving back to immediate expensing under Section 174A after capitalizing during 2022 through 2024, you may need to file Form 3115 to request a change in accounting method.13Internal Revenue Service. About Form 3115, Application for Change in Accounting Method

Keep supporting records for at least three years after filing the return claiming the credit.14Internal Revenue Service. Topic No. 305, Recordkeeping Hold them longer if credits are being carried forward. The IRS can examine the year a credit was generated even when it is used in a later year, so a 2026 credit finally applied in 2032 needs documentation surviving until at least 2035.